- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01360723
DNA Methylation and Arsenic-associated Urothelial Carcinoma
26. maj 2011 opdateret af: China Medical University Hospital
Comparison of DNA Methylation Between Urothelial Carcinoma and Healthy Controls
The investigators previously pointed out the significant association between urinary arsenic profiles and urothelial carcinoma (UC) risk through a 12-year follow-up study.
Further, the investigators observed the increased UC risk in people with lower plasma folate and higher homocysteine than those with higher plasma folate and lower homocysteine in 2010.
S-adenosylmethionine (SAM) is one factor included in one-carbon metabolism pathway and is the main donor of methyl group in cells.
The ratio of SAM and its metabolite S-adenosylhomocysteine (SAH) not only reflected the intake level of dietary folate but also demonstrated the extent of global DNA methylation.
These factors might play important roles in UC carcinogenesis.
The investigators would expect to take three years to explore the interactions among global DNA methylation, one-carbon metabolic pathway factors, urinary arsenic profiles, the polymorphisms and haplotype of Glycine N-methyltransferase (GNMT) and UC.
In the first year, the investigators would measure the levels of plasma folate, homocysteine, SAM and SAH and evaluate the associations between these factors and UC risk.
In the second year, the investigators would set up the method of immunohistochemistry stain and compare the differences between the global DNA methylation from bladder tissues and blood.
In the last year, this investigators would analyze the GNMT gene polymorphism and haplotype variation.
At the same time, the investigators would explore the impact of GNMT genetic variation and global DNA methylation on UC risk.
Based on the results from our research, the investigators might propose that the decreased ratio of SAM/SAH resulted in UC risk increased.
This mechanism might be through the changed levels of urinary arsenic profiles and global DNA methylation.
Studieoversigt
Status
Ukendt
Betingelser
Undersøgelsestype
Observationel
Tilmelding (Forventet)
600
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Taichung, Taiwan, 404
- Rekruttering
- Department of Urology, China Medical University Hospital
-
Kontakt:
- Chao-Hsiang Chuang, PhD
- Telefonnummer: 4439 886-4-22052121
- E-mail: urology8395@yahoo.com.tw
-
Ledende efterforsker:
- Chi-Jung Chung, PhD
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
21 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
This is a hosital-based case-control study.
Patients with urothelial carcinoma are recruited by pathological verification of UC was done by routine urological practice including endoscopic biopsy or surgical resection of urinary tract tumors followed by histopathological examination by board-certified pathologists.
Healthy controls without evidence of UC or any other malignancy were recurited including those receiving adult health examinations at China Medical University Hospital.
Beskrivelse
Inclusion Criteria:
- Clinical diagnosis of urothelial carcinoma
- The voluntary of participating the study
Exclusion Criteria:
- Age smaller than 20 years
- Pregnant women
- Not willing to participate the study because of their personal reasons
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
urothelial carcinoma
Pathological verification of UC was done by routine urological practice including endoscopic biopsy or surgical resection of urinary tract tumors followed by histopathological examination by board-certified pathologists.
|
|
Healthy controls group
Age and gender matched control subjects with no evidence of UC or any other malignancy were accrued from the hospital, recruiting people receiving adult health examinations at China Medical University Hospital.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
urothelial carcinoma
Tidsramme: up to three years
|
up to three years
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Efterforskere
- Ledende efterforsker: Chi-Jung Chung, PhD, Department of Health risk Management, China Medical University
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. maj 2011
Primær færdiggørelse (Forventet)
1. maj 2014
Datoer for studieregistrering
Først indsendt
24. maj 2011
Først indsendt, der opfyldte QC-kriterier
25. maj 2011
Først opslået (Skøn)
26. maj 2011
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
27. maj 2011
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
26. maj 2011
Sidst verificeret
1. maj 2011
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- DMR100-IRB-080
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Urothelialt karcinom
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk blæreurothelial karcinom | Metastatisk nyrebækken Urothelial Carcinom | Metastatisk Ureter Urothelial Carcinoma | Metastatisk Urethral Urothelial Carcinoma | Metastatisk Urothelial Carcinom | Lokalt avanceret blæreurothelial karcinom | Lokalt avanceret nyrebækken Urothelial Carcinoma | Lokalt... og andre forholdForenede Stater
-
University of Michigan Rogel Cancer CenterShenzhen HugeMed Medical Technical DevelopmentIkke rekrutterer endnuNyrebækken og Ureter Urothelial CarcinomaForenede Stater
-
National Cancer Institute (NCI)AfsluttetMetastatisk blæreurothelial karcinom | Metastatisk Ureter Urothelial Carcinoma | Stadie IV Blære Urothelial Carcinoma AJCC v7 | Metastatisk nyrebækken og Ureter Urothelial CarcinomaForenede Stater
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.Trukket tilbageMetastatisk blæreurothelial karcinom | Metastatisk nyrebækken Urothelial Carcinom | Metastatisk Ureter Urothelial Carcinoma | Metastatisk Urethral Urothelial Carcinoma | Uoperabelt nyrebækken Urothelial Carcinom | Uoperabelt Ureter Urothelial CarcinomaForenede Stater
-
Tyra Biosciences, IncRekrutteringLow Grade Upper Tract Urothelial CarcinomaForenede Stater
-
Changhai HospitalAktiv, ikke rekrutterendeNeoadjuverende terapi | Urothelial Carcinoma Ureter | Øvre urinvejsurothelial karcinomKina
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk Urothelial Carcinom | Stadie III Blære Urothelial Carcinoma AJCC v6 og v7 | Stadie IV Blære Urothelial Carcinoma AJCC v7 | Lokalt avanceret Urothelial Carcinom | Tilbagevendende Urothelial Carcinom | Uoperabelt Urothelial Carcinom | Avanceret Urothelial CarcinomForenede Stater
-
Barbara Ann Karmanos Cancer InstituteBristol-Myers SquibbAfsluttetStadie III Blære Urothelial Carcinoma AJCC v6 og v7 | Stadie IV Blære Urothelial Carcinoma AJCC v7 | Stadie II Blære Urothelial Carcinoma AJCC v6 og v7Forenede Stater
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendePemetrexed og Avelumab til behandling af patienter med MTAP-mangelfuld metastatisk urothelial cancerMetastatisk Urothelial Carcinom | Infiltrerende blære Urothelial Carcinoma, Plasmacytoid Variant | Infiltrerende blære Urothelial Carcinoma Sarcomatoid Variant | Infiltrerende blære-urothelial karcinom med kirteldifferentiering | Infiltrerende blære-urothelial carcinom med pladeepitel-differentiering og andre forholdForenede Stater
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk blæreurothelial karcinom | Metastatisk nyrebækken Urothelial Carcinom | Metastatisk Ureter Urothelial Carcinoma | Metastatisk Urethral Urothelial Carcinoma | Tilbagevendende blære-urothelial carcinom | Tilbagevendende nyrebækken Urothelial Carcinom | Tilbagevendende Ureter Urothelial Carcinoma og andre forholdForenede Stater